Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Wihlborgs to begin construction of Kvartetten in Hyllie

Wihlborgs is set to start construction on the next office project in Hyllie – Kvartetten (Pulpeten 5). 16,000 m² of modern office premises with a focus on people and the environment will be created a stone’s throw away from Hyllie station.Kvartetten will be an inspiring block with several facades, all with different identities and designs based on the Öresund region. The four facades will bring to mind the fertile farmland, the greenery of Malmö’s parks, Höganäs Keramik and the limestone of Limhamn. Everything that modern companies could wish for will be found in Kvartetten. Large,

Bemobi makes second filing for IPO in Brazil

Reference is made to the stock exchange release dated 22 October 2020, where it was announced that Otello's subsidiary Bemobi has made a preliminary filing for a listing of the Bemobi business in Brazil. The board has now decided to proceed with the listing process by making a second filing with the Brazilian Securities Commission and to commence a road show for the purpose of attract investors for an initial public offering ("IPO") of Bemobi. It is expected that the first day of trading will occur mid-February 2021, but investors should note that the listing is subject to market conditions

Lipidor and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor’s AKVANO[®] technology

STOCKHOLM, Sweden, 18 January 2021 – Lipidor AB (Nasdaq First North:LIPI) today announced that the Company has signed an exclusive licensing agreement with Cannassure Therapeutics Ltd. (TASE:CSURE), an Israeli company specializing in the development and manufacture of innovative medicinal cannabis products. Under the agreement, Cannassure has the exclusive right to use Lipidor's proprietary drug delivery technology AKVANO[®] in medicinal cannabis products for the treatment of selected indications such as psoriasis, atopic dermatitis, pain and lesions. Lipidor receives a royalty of 15-17.5% on

Wärtsilä’s reporting schedule for financial reports 2021

Wärtsilä Corporation, stock exchange release, 18 January 2021 at 9.15 am EETWärtsilä’s reporting schedule for financial reports 2021Wärtsilä will publish its financial reports for the year 2021 as follows: Interim Report January-March 2021 on Thursday, 22 April 2021Half-year Financial Report January-June 2021 on Tuesday, 20 July 2021Interim Report January-September 2021 on Tuesday, 26 October 2021Financial Statements Bulletin January-December 2021 on Friday, 28 January 2022 The Annual Report for the year 2020 will be published latest on 10 February 2021. Wärtsilä’s Annual

US Department of Defense (DoD) to support TRAUMAKINE development

· The DoD grants $6.1 million for the HIBISCUS study · Faron and the US Air Force to explore Traumakine’s wider potential to prevent multi-organ failure after ischemia and reperfusionCompany announcement, 18 January 2021 at 9.00 AM (EET)Inside information  TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the US Department of Defense (“DoD”) has selected the HIBISCUS Study to receive $6.1 million of funding from the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The Phase II/

Enhertu approved in the US for the treatment of patients with previously treated HER2-positive advanced gastric cancer

18 January 2021 07:00 GMT Enhertu approved in the US for the treatment of patients withpreviously treated HER2-positive advanced gastric cancer First HER2-directed medicine approved for patients with gastric cancer in a decade AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)'s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. In the US, gastric cancer is

Positive Phase 1 results in high-dose setanaxib trial

Genkyotex SA, a subsidiary of Calliditas Therapeutics AB (publ) (“Calliditas”) (Nasdaq OMX – CALTX; NASDAQ – CALT), today announced positive Phase 1 data demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib, Genkyotex’s lead asset.The Phase 1 study demonstrated that setanaxib is well tolerated at the doses tested, with no safety signal or dose-limiting toxicity being identified.  The results provide an opportunity for the company to pursue a pivotal Phase 2/3 clinical trial in patients with primary biliary cholangitis (PBC), based on interactions with the FDA.

Redwood Pharma announces intention to move to Nasdaq First North Growth Market stock exchange

The Board of Directors of Redwood Pharma AB (publ) (“Redwood Pharma” or “the Company”) today announces its intention to switch stock exchanges from Spotlight Stock Market to Nasdaq First North Growth Market in the spring of 2021.Redwood Pharma, active in drug development in ophthalmology, was listed on the Spotlight Stock Market in June 2016 and has since undergone strong business development through the continued validation of the original drug candidate RP101 and through the broadening of the product portfolio through the product candidate RP501. In 2020, clinical results were announced

MTG announces the terms of its rights issue

Not for release, publication or distribution, in whole or in part, directly or indirectly, in or into Australia, Canada, Japan, the United States or any other country where such publication, distribution or release would be unlawful or require additional documents to be prepared or registered or require any other actions to be taken, in addition to the requirements under Swedish law. This press release is not a prospectus or an offer for sale of securities. Securities may not be sold in the United States absent registration with the United States Securities and Exchange Commission or an

Serneke’s rights issue oversubscribed

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE SECTION “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.  Serneke Group AB (publ) (“Serneke” or the “Company”) announces that the Company’s subscription ratio in the rights issue amounts to 187 per cent. The subscription period for the rights

Radio Innovation is proud to announce a first field trial with Orange in the framework of a business acceleration

Sweden, January 18, 2021 - Swedish Tech Company Radio Innovation has become the first and so far only Swedish company that has been accepted into the Orange Fab Accelerator programme Radio Innovation will through the Orange Fab Accelerator programme get the opportunity to experiment on the field its technology with the objective to confirm the potential to meet Orange needs. “We only include companies into Orange Fab Accelerator that we anticipate will have the potential to make a substantial impact. We are confident that the solution developed by Radio

Naltrexone use decreases the risk of hospitalization in persons with alcohol use disorder

Naltrexone, used either alone or together with disulfiram or acamprosate, is associated with a decreased risk of hospitalization due to alcohol use disorder (AUD) when compared with non-use of AUD drugs, a new register-based study shows. The same associations were noticed for hospitalization due to any cause. Disulfiram use and polytherapy with two or more drugs indicated for AUD was associated with a decreased risk of hospitalization due to alcohol-related somatic causes. None of the studied medications were associated with mortality or work disability (sickness absence or disability

Cloudberry Clean Energy AS | Investor presentation

Oslo, Norway, 18 January 2021: Cloudberry Clean Energy AS (“Cloudberry” or the “Company”) is a Nordic renewable energy company. Cloudberry provides growth and value creation by owning, developing and operating renewable energy assets in Norway and Sweden. The Company seeks to grow both organically and inorganically, through maturing and executing on its portfolio of hydro and wind power assets. The portfolio, which ranges from undeveloped projects to producing assets, represents a significant growth and value creation potential.Cloudberry has today published an updated investor presentation

FlexQube receives an order worth $346 000 with the potential for more than $700 000 total

Aludyne Montague, LLC located in Michigan, USA, has placed an order with FlexQube worth $346 000 for the first phase of a logistic project.  The second phase of the project is right now planned for the latter part of 2021 and the total potential order value is a bit more than $700 000. The order consists of FlexQube carts and Liftrunner C-frames. The order will be delivered in Q2 of 2021.  Anders Fogelberg, CEO at FlexQube, comments: “This is the first major order we have received for a combination of Liftrunner C-frames and FlexQube carts since we became the exclusive dealer for

Kesko’s sales in December

Kesko Group's sales totalled €886.4 million in December 2020, representing an increase of 10.7% in comparable terms on the previous year.“Sales growth continued in all Kesko divisions in December. Sales to K-food stores grew by 14.2% in the grocery trade. Growth in the building and technical trade was strong in all operating countries, totalling 17.2% in comprable terms. Sales in the car trade increased by 21.4%, and the demand for electric cars in particular continued to be good. Sales development was impacted by the fact that December 2020 had more delivery days than December 2019,” says

Natural exposure through everyday cosmetics — Kiilto and Uute Scientific Oy join forces

Kiilto has agreed on collaboration with Uute Scientific Oy. The idea is to study how health-promoting, everyday natural exposure can be incorporated into Kiilto's consumer products.Studies have shown that multiple microbial exposures protect humans from autoimmune diseases and illnesses, including allergies, rheumatoid arthritis, psoriasis, celiac disease, type 1 diabetes and many intestinal problems. In practice, multiple microbial exposures means daily contact with nature. Uute Scientific Oy, which grew out of the ADELE project between the universities of Helsinki and Tampere, produces

Bonava's operating profit for the fourth quarter and full year 2020 is expected to be above market expectations

Net sales for the fourth quarter of 2020 are expected to amount to about SEK 7.5 billion (6.5) and operating profit to SEK 860 - 910 million (693)*. For the full year 2020, net sales are expected to amount to about SEK 17.0 billion (15.5) and operating profit to SEK 1,075 – 1,125 million (1,202)*. Operating profit has been positively affected by more profit-recognised housing units in combination with lower costs and the fact that the previously communicated measures in Finland have had an effect.Bonava recognises revenue and earnings from housing sales when sold and completed housing units

Information on the over-allotment option and end of the stabilisation period

THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES IN ACCORDANCE WITH APPLICABLE LAW. PLEASE REFER TO "IMPORTANT INFORMATION" AT THE END OF THE PRESS RELEASE.ABG Sundal Collier AB ("ABGSC") notifies regarding the exercise of the over-allotment option in

Nobia trading update

Net sales and operating profit for Nobia in the fourth quarter 2020 will exceed expectations due to strong trading in the Nordic and Central Europe regions.Net sales for the Group are estimated at SEK 3,449m (SEK 3,445m in Q4 2019) with an organic growth of approximately 5 per cent. The operating profit excluding items affecting comparability, is expected to be in the range of SEK 290 - 300m (SEK 214m in Q4 2019 including SEK -30m of non-recurring cost). Items affecting comparability for the quarter is estimated to amount to SEK -144m. Market conditions since December are however

Fiskars provides preliminary information for 2020

Fiskars CorporationInsider informationJanuary 15, 2021 at 19:15 EET Fiskars provides preliminary information for 2020 As the year 2020 has been highly volatile due to the COVID-19 pandemic, Fiskars Corporation provides preliminary information on figures for 2020. The year ended in accordance with the Company’s expectation. Net sales is expected to be approximately EUR 1,116 million (2019: 1,090.4), comparable EBITA approximately EUR 137 million (90.6) and operating profit (EBIT) approximately EUR 98 million (60.1). The figures are based on preliminary, unaudited information. “

Speqta’s founders sell parts of their holdings to repay loans

Speqta’s (“SPEQT”) two founders have sold parts of their holdings in Speqta to repay private loans which aimed to finance Speqta’s expansion.Speqta’s two founders Andereas Friis and Jonas Söderqvist have on Friday 15 January 2021 sold parts of their holdings in Speqta. The reason for the sale is to repay private loans they had initially taken in 2017 when they signed a senior convertible note, issued by the general meeting. The convertibles notes were exchanged for shares in 2019 and the shares then became collaterals for the private loans. When the loans now are to be repaid, the

PIHLAJALINNA PLC: SHARE REPURCHASE 15.1.2021

Pihlajalinna Plc Stock Exchange Release 15.1.2021 PIHLAJALINNA PLC: SHARE REPURCHASE 15.1.2021 In the NASDAQ OMX Helsinki Trade date           15.1.2021Bourse trade         BuyShare                  PIHLISAmount             20 000 SharesAverage price/ share    9,6087 EURTotal cost            192 174,00 EUR Company now holds a total of 22 294 sharesincluding the shares repurchased on 15.1.2021 On behalf of

Throw Down star champions Staffordshire University design course

TV star and master potter Keith Brymer Jones is continuing to talk up the Potteries by lavishing praise on Staffordshire University’s 3D Designer Maker course.The Great Pottery Throw Down judge talks about his links to Stoke-on-Trent and Staffordshire University in a video shot on campus while he was filming for the Channel 4 show which is being aired on Sunday evenings. Keith tweeted : "I have a lot of respect for @3ddesignstaffs . If you have any sons or daughters thinking of a design

#21-16 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

There are no items matching the current filter
There are no more items matching the current filter
Back to top